全球新冠疫苗進展加快 生物疫苗板塊盤中持續拉昇
格隆匯12月3日丨博雅生物、天壇生物、康泰生物漲超6%領漲,華蘭生物、雙林生物漲近6%,復星醫藥、智飛生物、萬孚生物均明顯上漲。全球新冠疫苗進展加快,輝瑞疫苗在英獲批,俄產新冠疫苗下週也將正式在俄接種。國內方面,國務院副總理孫春蘭、國務委員王勇2日在北京調研新冠病毒疫苗研發和生產準備工作時稱,目前5條技術路線的14個疫苗進入臨牀試驗,其中5個疫苗正在按程序按標準開展Ⅲ期臨牀試驗,緊急使用、生產準備各項工作有序推進。下一步,要確保疫苗安全有效、經得起各方面檢驗,要做好大規模生產準備。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.